

## **PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT**

Summary of risk management plan for VAXELIS® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Outer Membrane Protein Complex), and Hepatitis B (Recombinant) Vaccine adsorbed (DTaP-HB-IPV-Hib).

This is a summary of the risk management plan (RMP) for VAXELIS® (DTaP-HB-IPV-Hib). The RMP details important risks of VAXELIS® (DTaP-HB-IPV-Hib) and how more information will be obtained about VAXELIS® (DTaP-HB-IPV-Hib) risks and uncertainties (missing information).

VAXELIS® (DTaP-HB-IPV-Hib) summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how VAXELIS® (DTaP-HB-IPV-Hib) should be used.

This summary of the RMP for VAXELIS® (DTaP-HB-IPV-Hib) should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of VAXELIS® (DTaP-HB-IPV-Hib) RMP.

### **I. The Medicine and What it is Used For**

VAXELIS® (DTaP-HB-IPV-Hib) is authorised for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by *Haemophilus influenzae* type b (Hib). It contains diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and *Haemophilus influenzae* type b conjugate vaccine (adsorbed) as the active substance and it is given by intramuscular administration.

Further information about the evaluation of VAXELIS® (DTaP-HB-IPV-Hib) benefits can be found in VAXELIS® (DTaP-HB-IPV-Hib) EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage: <https://www.ema.europa.eu/en/medicines/human/EPAR/vaxelis>.

### **II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks**

Important risks of VAXELIS® (DTaP-HB-IPV-Hib), together with measures to minimise such risks and the proposed studies for learning more about VAXELIS® (DTaP-HB-IPV-Hib) risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## **II.A List of Important Risks and Missing Information**

Important risks of VAXELIS® (DTaP-HB-IPV-Hib) are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of VAXELIS® (DTaP-HB-IPV-Hib). Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Based on scientific information to date and the latest guidance on Risk Management Planning from the EMA, the Potential Risks and the Missing Information have been removed:

The risks are fully characterized and appropriately managed through labeling.

There is no reasonable expectation that any pharmacovigilance activity can further characterize the previously listed Potential risks and Missing Information.

**Table II.A.1: List of Important Risks and Missing Information**

<b>List of Important Risks and Missing Information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

**II.B Summary of Important Risks**

The safety information in the proposed Prescribing Information is aligned to the reference medicinal product. There are no identified risks, potential risks, or missing information in this RMP.

**II.C Post-Authorisation Development Plan**

**II.C.1 Studies Which are Conditions of the Marketing Authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of VAXELIS® (DTaP-HB-IPV-Hib).

**II.C.2 Other Studies in Post-Authorisation Development Plan**

There are no studies required for VAXELIS® (DTaP-HB-IPV-Hib).